Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin for Prevention of Cardiac Allograft Vasculopathy
NCT01157949Phase 3Withdrawn
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Nov 2010
- Primary completion
- Nov 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of antithymocyte globulin in cardiac allograft vasculopathy (CAV), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Incidence of Cardiac Allograft Vasculopathy at 12 months. Planned start Nov 2010; status: withdrawn.
02
Drugs
antithymocyte globulin
03
Conditions
cardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT01157949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01157949.